Recursion Pharmaceuticals Shares Drop After Nvidia Exits Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2025
0mins
Should l Buy RXRX?
Source: Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) shares fell 7.51% during regular trading, hitting a 52-week low.
The decline follows Nvidia's recent disclosure that it exited its equity stake in Recursion, which has raised concerns among investors about the company's future prospects. This move has contributed to a broader market sentiment shift, particularly affecting tech stocks, as investors react to Nvidia's changing investment strategy.
The exit of Nvidia, a significant player in the tech industry, may lead to increased volatility for Recursion and similar companies, potentially impacting investor confidence and market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.320
Low
5.00
Averages
7.75
High
11.00
Current: 3.320
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
Recursion Pharmaceuticals Q1 2026 Earnings Call Insights
- Strong Financial Position: Recursion Pharmaceuticals closed Q1 2026 with $665 million in cash and equivalents, providing an operational runway through early 2028, demonstrating effective financial management and sustainability.
- Significant Clinical Progress: The company has dosed the first patient in the Phase I trial for REC-4539, and early tolerability for REC-1245 shows no dose-limiting toxicities, indicating potential safety and efficacy in drug development.
- Effective Cost Control: Recursion maintains its cash operating expense guidance for 2026 at under $390 million, achieving a 30% year-over-year reduction, reflecting a strategic focus on financial discipline and capital allocation.
- Optimistic Partnership Outlook: Management expects multiple clinical readouts in the next 12 to 18 months and is optimistic about partnered projects with Sanofi, committing to share updates in the next two months, indicating proactive strategic collaboration.
See More
Recursion Pharmaceuticals Q1 Earnings Analysis
- Earnings Performance: Recursion Pharmaceuticals reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.04, yet revenue of $6.47 million fell short by $9.31 million, reflecting significant challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, the company had $665.2 million in cash and equivalents, down from $753.9 million as of December 31, 2025, indicating pressure on financial management that could impact future operational capabilities.
- Operating Expense Control: The cash operating expense for Q1 was $85.1 million, significantly lower than $120.2 million in the same period of 2025, demonstrating some success in cost control despite overall insufficient revenue.
- Funding Outlook: The company reiterated its guidance of less than $390 million in operational cash burn for 2026, expecting its cash runway to extend into early 2028, indicating a relatively stable financial plan without additional financing.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Healthcare Transformation: The Rise of Data-Driven Models
- Tempus AI's Market Potential: Tempus AI is collecting clinical and genomic data, with projected revenue of $1.27 billion in 2025, an 83% increase, positioning itself as a core player in precision medicine that enhances smart and precise medical decision-making.
- Recursion Pharmaceuticals' Innovative Model: Recursion Pharmaceuticals generated approximately $74.7 million in revenue last year through partnerships with Bayer and Roche, despite operating expenses exceeding $722 million, its innovative drug discovery model is poised to fundamentally change the dynamics of the pharmaceutical industry.
- Axsome Therapeutics' Rapid Growth: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, reporting $191.2 million in revenue for Q1 2026, a 57% year-over-year increase, with FDA approval for Alzheimer's agitation potentially adding $2 billion in additional sales.
- Integration Trends in Future Healthcare: These three companies represent different layers of healthcare transformation, with Tempus AI focusing on data and personalization, Recursion Pharmaceuticals on automated drug discovery, and Axsome Therapeutics on enhancing treatment efficacy, collectively driving the healthcare system towards greater precision and efficiency.
See More
Tempus AI and Others Poised to Transform Precision Medicine
- Tempus AI's Growth Potential: Tempus AI is projected to reach $1.27 billion in revenue by 2025, an 83% increase from 2024, by collecting clinical and genomic data to assist doctors in making more precise treatment decisions, thereby positioning itself as a core player in precision medicine.
- Revolutionizing Drug Discovery: Recursion Pharmaceuticals aims to disrupt traditional drug discovery methods by integrating high-throughput automation and machine learning; despite operating expenses exceeding $722 million in 2025, its partnerships with Bayer and Roche generated approximately $74.7 million in revenue, indicating significant market potential.
- Rapid Advancement of Axsome Therapeutics: Axsome Therapeutics' Auvelity drug shows a rapid onset of action for major depressive disorder, with FDA approval for treating Alzheimer's agitation expected to generate an additional $2 billion in annual sales, highlighting its clinical advantage and market opportunity.
- Transformation of Future Healthcare Systems: These three companies represent different layers of the healthcare industry's evolution, combining data-driven and precision treatment trends, and by 2030, the winners will be those who own the data, accelerate discovery, and deliver real outcomes, fundamentally reshaping the healthcare landscape.
See More
Recursion Pharmaceuticals Q1 2026 Earnings Call Insights
- Strong Financial Position: Recursion Pharmaceuticals closed Q1 2026 with $665 million in cash and equivalents, providing an operational runway through early 2028, demonstrating effective financial management and sustainability.
- Significant Clinical Progress: The company has dosed the first patient in the Phase I trial for REC-4539, and early tolerability for REC-1245 shows no dose-limiting toxicities, indicating potential safety and efficacy in drug development.
- Effective Cost Control: Recursion maintains its cash operating expense guidance for 2026 at under $390 million, achieving a 30% year-over-year reduction, reflecting a strategic focus on financial discipline and capital allocation.
- Optimistic Partnership Outlook: Management expects multiple clinical readouts in the next 12 to 18 months and is optimistic about partnered projects with Sanofi, committing to share updates in the next two months, indicating proactive strategic collaboration.
See More
Recursion Pharmaceuticals Q1 Earnings Analysis
- Earnings Performance: Recursion Pharmaceuticals reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.04, yet revenue of $6.47 million fell short by $9.31 million, reflecting significant challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, the company had $665.2 million in cash and equivalents, down from $753.9 million as of December 31, 2025, indicating pressure on financial management that could impact future operational capabilities.
- Operating Expense Control: The cash operating expense for Q1 was $85.1 million, significantly lower than $120.2 million in the same period of 2025, demonstrating some success in cost control despite overall insufficient revenue.
- Funding Outlook: The company reiterated its guidance of less than $390 million in operational cash burn for 2026, expecting its cash runway to extend into early 2028, indicating a relatively stable financial plan without additional financing.
See More
